Recently, our group screened compound libraries and identified kenpaullone, a pharmacological GSK3β inhibitor that attenuates the survival of patient-derived glioblastoma SCs via the c-Myc-mediated pathway [122]. This evidence concerns the gene GSK3B and glioblastoma.